With much-awaited approval of biosimilar interchangeability by FDA, the dynamics in the much nascent US biosimilars market is about to change with long-lasting price competition. The report ?Global Biosimilar Market by Classes (Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon (IFN) & Markets (Developed & Emerging)- Industry Outlook 2020? provides an in-depth analysis of global biosimilars market focusing on key segments detailing approved and upcoming biosimilar products. Market outlook for aforementioned biosimilar classes has been provided for the period 2017-20.

The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities at the global and regional level. The report has been segmented as following:-

Market Segmentation by Classes
? Insulin
? Erythropoietin (EPO)
? Human Growth Hormone (HGH)
? Granulocyte- Colony Stimulating Factor (G-CSF)
? Monoclonal Antibody (mAb)
? Interferon (IFN)
Market Segmentation by Geography
? Developed Markets - Europe and the US
? Emerging Markets - China & India
Key Vendors
? Sandoz
? Hospira
? TEVA
? Celltrion
? Biocad
? Dong-A Pharmaceutical Co., Ltd.
? Stada

Biosimilars are biopharmaceutical drugs that are highly similar to already approved biological product (also known as biological reference product). Biosimilars are unique and can never be identical to the reference product as these are grown in living cells. Biosimilars are not generics but have close proximity to generic version of various biologics. The emergence of biologics had already revolutionized treatment options for large variety of diseases. There is increased market opportunity for biosimilars with majority of biologics losing exclusivity in upcoming years. Biosimilars has substantial potential to increase access to biological therapies while enhancing cost-effectiveness of healthcare systems globally.
Growing demand for biosimilars and biologics worldwide is demonstrated by magnitude of biological patent expiries, cost savings associated with use of biosimilars and increased use of biosimilars for treatment of chronic diseases. Major market restraints biosimilars market are high cost of development of biosimilars, regulatory uncertainty, lower adoption rate of biosimilars and manufacturer skill gap. Some of the leading industry trends and developments include new biosimilar products dominated by Large Globals, increased focus on pharmerging markets and issuance of much-awaited biosimilar interchangeability guidance by FDA.
The report provides information on the current scenario, detailed market outlook of the global biosimilar market. Detailed analysis of Biosimilar market segmentation by application area - Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon (IFN) has been covered in the report. Future forecasts of major segments as well as biosimilar markets in developed and emerging nations till 2020 is provided in the report. Furthermore, key industry players have been prudently analyzed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the market include Biocad, TEVA, Celltrion, Sandoz, Dong-A Pharmaceutical Co., Ltd., Hospira, Intas, Stada Arzneimittel, among others. Sandoz, Hospira, TEVA, Celltrion, Biocad and Dong-A Pharmaceutical Co., Ltd. are profiled herein based on attributes such as business overview, product pipeline, financial and business strategies. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global biosimilars market in both developed and emerging economies.